April 18th 2025
The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Stem Cell Transplants Delay Disease Reactivation in Patients with Aggressive Multiple Sclerosis
February 2nd 2017Patients with relapsing-remitting multiple sclerosis (MS) who are treated with currently available disease-modifying drugs (DMARDs) usually experience disease reactivation within the first five years of treatment follow-up. Many of the available treatments for MS only confer complete control of disease activity in a small percentage of patients.
Impact of Manufacturing-Scale Freeze-Thaw Conditions on a mAb Solution
February 1st 2017The objective of this study was to assess the impact of manufacturing-scale, freeze-thaw conditions on aggregation and subvisible particle formation of a monoclonal antibody solution (mAb-A; IgG1) using a small-scale model.